Table 3.

Association between rs1800797 and risk for lung cancer in the GENEVA dataset.

Variable	Control (n)a	Case (n)a	OR (95% CI)	p-Value
Overall	0.67 ± 0.67 (2,725)	0.70 ± 0.67 (2,522)	1.10 (1.01, 1.20)	0.045b
Smoking statusc
Never smokers	0.60 ± 0.63 (633)	0.70 ± 0.64 (138)	1.41 (1.05, 1.91)	0.024d
Former smokers	0.67 ± 0.68 (1,125)	0.72 ± 0.69 (1,204)	1.08 (0.95, 1.24)	0.24d
Current smokers	0.70 ± 0.68 (967)	0.67 ± 0.66 (1,180)	1.06 (0.92, 1.22)	0.43d
Histology
Adenocarcinoma	0.67 ± 0.67 (2,725)	0.72 ± 0.69 (986)	1.16 (1.04, 1.31)	0.0091d
Squamous cell carcinoma	0.67 ± 0.67 (2,725)	0.69 ± 0.67 (582)	1.08 (0.93, 1.25)	0.33d
Small cell	0.67 ± 0.67 (2,725)	0.62 ± 0.65 (256)	0.90 (0.73, 1.11)	0.32d
Others	0.67 ± 0.67 (2,725)	0.70 ± 0.67 (698)	1.04 (0.91, 1.19)	0.59d
Abbreviations: CI, confidence interval; GENEVA, Gene Environment Association Studies; OR, odds ratio. aA allele dosage for rs1800797 presented as mean ± standard deviation. bAdjustment for age, sex, smoking status, pack-years, and cohort was included in logistic regression models. cThe interaction terms between never versus current smokers and rs1800797 and between former versus current smokers and rs1800797 were included together in the logistic regression with statistical significance identified for both interaction terms (p-values = 0.050 and 0.029, respectively). dAdjustment for age, sex, pack-years, and cohort was included in logistic regression models.